Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
- Conditions
- Stage III Lung Cancer AJCC v8EGFR Mutation-Related TumorsStage IIIB Lung Cancer AJCC v8Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT05498389
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05263180
- Locations
- 🇦🇺
Peninsula and South Eastern Haematology & Oncology Group, Frankston, Australia
🇦🇺GenesisCareNorthShore, Leonards Hill, Australia
🇦🇺Blacktown Hospital, Sydney, Australia
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
- Conditions
- NeoplasmsNeoplasm MetastasisMetastatic Gastrointestinal Carcinoid Tumor
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 152
- Registration Number
- NCT05176665
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳Beijing cancer Hospital, Beijing, Beijing, China
🇨🇳Nanfang Hospital, Guangzhou, Guangdong, China
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04735575
- Locations
- 🇦🇺
Sunshine Coast Haematology and Oncology Clinic (SCHOC), Buderim, Queensland, Australia
🇦🇺Epworth Healthcare, Richmond, Victoria, Australia
🇦🇺One Clinical Research (OCR), Nedlands, Western Australia, Australia
A Study of EMB-02 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT04618393
- Locations
- 🇺🇸
University of Colorado Health Medical Group, Colorado Springs, Colorado, United States
🇺🇸Prisma Health-Upstate, Greenville, South Carolina, United States
🇦🇺Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
- Prev
- 1
- 2
- Next